Table 2.

Network meta‐analyses for sustained response (efficacy) and all‐cause discontinuation (acceptability) of various treatment modalities

COM→COM	1.92 (1.04‐3.54)	1.31 (0.68‐2.51)	0.95 (0.57‐1.58)	0.68 (0.43‐1.07)	1.43 (0.75‐2.75)	0.81 (0.19‐3.55)	1.45 (0.78‐2.68)	0.33 (0.18‐0.60)
1.47 (0.85‐2.53)	COM→nat	0.68 (0.44‐1.07)	0.50 (0.25‐0.97)	0.35 (0.20‐0.64)	0.75 (0.48‐1.16)	0.42 (0.09‐1.95)	0.76 (0.56‐1.02)	0.17 (0.08‐0.35)
1.59 (0.91‐2.76)	1.08 (0.74‐1.56)	PSY→nat	0.73 (0.36‐1.45)	0.52 (0.28‐0.94)	1.09 (0.70‐1.70)	0.62 (0.13‐2.88)	1.11 (0.68‐1.81)	0.25 (0.12‐0.51)
1.65 (1.04‐2.61)	1.12 (0.62‐2.03)	1.04 (0.57‐1.88)	PSY→PSY	0.71 (0.45‐1.14)	1.50 (0.74‐3.04)	0.85 (0.20‐3.57)	1.52 (0.78‐2.99)	0.34 (0.19‐0.64)
2.52 (1.66‐3.85)	1.72 (1.04‐2.84)	1.59 (0.98‐2.60)	1.53 (1.00‐2.35)	PHA→PHA	2.11 (1.13‐3.91)	1.20 (0.29‐4.99)	2.13 (1.19‐3.84)	0.48 (0.32‐0.73)
2.64 (1.46‐4.76)	1.80 (1.21‐2.67)	1.66 (1.13‐2.44)	1.60 (0.85‐3.02)	1.05 (0.61‐1.81)	PHA→nat	0.57 (0.12‐2.65)	1.01 (0.62‐1.67)	0.23 (0.11‐0.48)
2.97 (0.71‐12.45)	2.02 (0.46‐8.79)	1.87 (0.43‐8.13)	1.80 (0.45‐7.26)	1.18 (0.29‐4.76)	1.12 (0.25‐4.98)	PHA→COM	1.78 (0.39‐8.21)	0.40 (0.09‐1.78)
2.90 (1.68‐5.01)	1.97 (1.51‐2.58)	1.83 (1.20‐2.78)	1.76 (0.97‐3.21)	1.15 (0.69‐1.92)	1.10 (0.70‐1.73)	0.98 (0.22‐4.27)	STD	0.23 (0.11‐0.46)
5.05 (3.00‐8.51)	3.44 (1.91‐6.18)	3.18 (1.79‐5.66)	3.06 (1.81‐5.18)	2.00 (1.47‐2.73)	1.91 (1.02‐3.57)	1.70 (0.41‐7.13)	1.74 (0.96‐3.16)	Pill placebo

Values are odds ratios (ORs) with 95% confidence intervals. OR>1 in the lower‐left half indicates that the treatment in the column is more effective than the treatment in the row. OR<1 in the upper‐right half indicates that the treatment in the row is more acceptable than the treatment in the column. COM – combination therapies, PHA – pharmacotherapies, PSY – psychotherapies, STD – standard treatment in primary or secondary care, nat – discretionary treatment